Paris, October 23rd 2012 - Theradiag, the theranostics and in vitro diagnostics company focused on autoimmune diseases, has just signed a partnership agreement with Sebia.
Within the framework of this partnership, Theradiag will play an advisory role in development and will be responsible for the scale-up and production of a future diagnostic kit. According to the terms of the agreement, Theradiag will receive royalties on sales and revenues for future production.
"We are delighted to have formed a partnership with Sebia that highlights our expertise and acknowledges Theradiag's development and production capabilities in the field of diagnostics," stressed Michel Finance, Theradiag's Chief Executive Officer.
"The collaboration with Theradiag seemed a natural fit to us when we needed to find a partner for this new diagnostic kit. The two companies have complementary areas of expertise that will provide the necessary synergies for rapid development of the project, all within an area of geographical proximity," added Benoît Adelus, Sebia's Chairman and Chief Executive Officer.
Theradiag has over 25 years of experience in the diagnostic market, especially for autoimmune diseases. It is currently moving into the theranostics market with the goal of improving monitoring for biologic treatments for autoimmune diseases in particular.
Theradiag, a recent positioning on the theranostic market
Thanks to an expertise in IVD and autoimmune diseases, from development to sales via regulatory phases, Theradiag will focus its development strategy on theranostics tests for biotherapy monitoring. Theradiag was CE marked in 2011 and marketed a new range of products, Lisa Tracker, for improving the monitoring of treatments of patients being treated with Anti-TNF.
New theranostics products are currently being developed.
The company is based in Marne la Vallée (near Paris, France) and currently has 50 employees.
For more information about the company, visit our website: www.theradiag.com
For more than 40 years, Sebia, a global leader in protein electrophoresis, has been developing, manufacturing, and marketing reagents and instruments for in vitro diagnosis of certain cancers, inflammatory diseases, metabolic disorders, and hemoglobinopathies. Sebia's expertise in electrophoresis techniques has allowed it to maintain a continuous research & development program, enabling it to provide genuine solutions to all kinds of laboratories.
Recently, Sebia has adapted that highly successful technology for the field of diabetes, in order to meet the growing global demand for more accurate and reproducible methods of measuring HbA1c levels.
For further information: www.sebia.com
Theradiag Press contacts:
+33 6 64 18 99 59 / email@example.com
+ 33 (0) 1 42 68 86 41 /firstname.lastname@example.org